Chong Kun Dang wins approval to sell anemia treatment biosimilar 'Nesbell' in Japan
Chong Kun Dang wins approval to sell anemia treatment biosimilar 'Nesbell' in Japan
  • Kim Min-jee
  • 승인 2019.09.25 10:51
  • 댓글 0
이 기사를 공유합니다

Chong Kun Dang has won an approval from Japan's Ministry of Health, Labor and Welfare to manufacture and sell the world's first second-generation anemia treatment biosimilar, "Nesbell."

In April last year, Chong Kun Dang signed a contract with the Japanese subsidiary of U.S. global pharmaceutical company Mylan N.V. to conduct clinical trials for Nesbel's authorization in Japan, grant product licenses, and sell products exclusively, and applied for approval to the Japanese ministry in October.

Chong Kun Dang will export Nesbell's finished products to the Japanese subsidiary of Mylan, while the Japanese company will release the products in December after undergoing a drug price decision process.

It is a second-generation, sustainable product that uses genetic engineering technology to significantly reduce the frequency of drug administration to improve patients' convenience, and launched the product in September after having already received an approval for an item license in Korea.

Chong Kun Dang is set to enter the global market based on Nesbell's legal patents acquired in nine countries, including the United States, Europe and Japan, starting at home in 2014.

"Nesbell is the world's first NESP biosimilar and the company's first biomedical drug to be approved for manufacturing and selling in Japan. We are planning to speed up our advance into the 3.6 trillion won global market starting with the 550 billion won market in Japan," a company official said.

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • URL: / Editorial Div. 02-578-0434 / 010-2442-9446. Email:
  • Publisher: Monica Younsoo Chung. CEO: Lee Kap-soo. Editor: Jung Yeon-jin. Juvenile Protection Manager: Yeon Choul-woong.
  • IT Times Canada: Willow St. Vancouver BC, Canada / 070-7008-0005.
  • Copyright(C) Korea IT Times, Allrights reserved.